位置:首页 > 产品库 > Entacapone-d10
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Entacapone-d10
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Entacapone-d10图片
规格:98%
分子量:315.4
包装与价格:
包装价格(元)
500ug询价
1mg询价

Entacapone-d10 是氘标记的 Entacapone。
货号:ajcx22420
CAS:1185241-19-3
分子式:C14H5D10N3O5
分子量:315.4
溶解度:DMSO: Slightly soluble,Methanol: Slightly soluble
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Entacapone-d10is intended for use as an internal standard for the quantification of entacapone by GC- or LC-MS. Entacapone is a reversible catechol O-methyltransferase (COMT) inhibitor (IC50s = 10, 10, 20, and 160 nM for rat duodenum, brain, erythrocyte, and liver COMT, respectively).1It is selective for COMT over monoamine oxidase A (MAO-A) and MAO-B and phenolsulphotransferase M (PST-M) and PST-P (IC50s = >50 µM). Entacapone (10 mg/kg), in combination with L-DOPA and carbidopa , reduces 3-O-methyldopa (3-OMD) levels in the rat striatum and hypothalamus to 52 and 27%, respectively, of the levels in control animals receiving only L-DOPA and carbidopa.2In a 6-OHDA rat model of Parkinson's disease, entacapone (10 mg/kg), in combination with L-DOPA and benserazide , increases contralateral turning behavior and striatal extracellular dopamine levels.3Entacapone also inhibits contraction of colon longitudinal muscle explants from a 6-OHDA rat model of Parkinson's disease (EC50= 200 µM).4Formulations containing entacapone have been used in the treatment of Parkinson's disease.


1.Nissinen, E., LindÉn, I.B., Schultz, E., et al.Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacaponeNaunyn Schmiedebergs Arch. Pharmacol.346(3)262-266(1992) 2.MÄnnistÖ, P.T., Tuomainen, P., and Tuominen, R.K.Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the ratBr. J. Pharmacol.105(3)569-574(1992) 3.Gerlach, M., van den Buuse, M., Blaha, C., et al.Entacapone increases and prolongs the central effects of L-DOPA in the 6-hydroxydopamine-lesioned ratNaunyn Schmiedebergs Arch. Pharmacol.370(5)388-394(2004) 4.Li, L.-S., Liu, C.-Z., Xu, J.-D., et al.Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's diseaseWorld J. Gastroenterol.21(12)3509-3518(2015)

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024